OpenAI acquires Torch Health for USD 60,000,000 (2026)

Deal facts

Buyer: OpenAI
Target: Torch Health
Deal value: USD 60,000,000
Announced: 12 January 2026
Status: Completed
Sector: Healthcare
Country: United States
Consideration: Not stated

Sources

NEWS_WIRE · ai-acquirers-2026:openai:torch-health:2026-01-12

What we know

OpenAI acquired Torch Health as part of the 2026 wave of AI companies buying other AI and AI-adjacent startups. OpenAI bought an AI-powered health software startup focused on unified medical records. The reported value was USD 60,000,000.

For founders, the useful signal is not the headline multiple. It is the buyer logic: capability, speed, talent, geography or product depth can matter more than a simple earnings multiple when a strategic buyer has a gap to close.

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

12 Jan 2026CompletedClosed
OpenAI acquires Torch Health
OpenAI bought an AI-powered health software startup focused on unified medical records.
News wire

OpinionExit Mode editorial

We see OpenAI’s purchase of Torch Health for $60 million, announced on 12 January 2026 and now completed, as a clear signal that the AI giant is moving decisively into the healthcare arena. The deal brings together a world-leading artificial-intelligence platform and a specialist health-tech provider, creating a combined capability that could reshape data-driven care. For an SME founder working in health technology, the headline alone tells you that the market is now open to AI-enabled solutions at a scale previously reserved for large pharmaceutical groups.

Our view is that OpenAI is not merely buying a product; it is acquiring a data-rich patient platform that can accelerate the training of medical models. The move validates the belief that AI can improve diagnostics, triage and personalised treatment, and it will likely encourage other technology firms to look for health-focused acquisitions. Founders should note that the valuation, $60 million in cash, places a premium on data assets and regulatory licences, suggesting that building a compliant data pipeline can be as valuable as any single algorithm.

From a commercial and regulatory perspective, a cross-border acquisition in the health sector will almost certainly trigger competition scrutiny. In the UK, the CMA would assess whether the combined entity could lessen competition in AI-driven health services, while EU authorities would run a parallel review if the target has a European footprint. Data-protection obligations under the UK GDPR and the EU’s medical-device regulations will also be examined, meaning that any change-of-control covenants will need to address ongoing compliance. Although the public filing does not disclose escrow or earn-out terms, founders should expect that such mechanisms are common in deals where future regulatory approval is uncertain.

For the SME founder reading this, the immediate step is to audit your own data-governance framework. Identify any patient-level datasets you hold, map the legal bases you rely on, and document the controls you have in place. Schedule a 30-minute session with your compliance officer or legal adviser this week to confirm that your data practices would survive the same level of scrutiny that a deal of this size will face. This preparation will put you in a stronger position whether you aim to attract a strategic partner or simply want to protect your business from future regulatory risk.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More strategic acquisition deals More from OpenAI All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Not statedCompletedHealthcare

Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited

Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…

Buyer: Circle Health Holdings Limited
Target: CHC Healthcare Holdings Limited
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

15 October 2026CompletedHealthcare

Cronos Group Inc. to acquire CanAdelaar B.V.

Cronos Group Inc. has agreed to acquire CanAdelaar B.V. in a strategic acquisition within the healthcare sector. The Canadian buyer will purchase the Dutch target for a…

Buyer: Cronos Group Inc.
Target: CanAdelaar B.V.
Deal value: EUR 57,500,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Netherlands deals

13 October 2026CompletedHealthcare

Alaunos Therapeutics, Inc. to acquire Velaris Therapeutics, Inc.

Alaunos Therapeutics, Inc. has agreed to acquire Velaris Therapeutics, Inc. in a strategic acquisition. The transaction was announced on 13 October 2026 and was complete…

Buyer: Alaunos Therapeutics, Inc.
Target: Velaris Therapeutics, Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

11 October 2026Firm intentionHealthcare

STERIS Corporation to acquire Xodus Medical, Inc.

STERIS Corporation has agreed to acquire Xodus Medical, Inc. in a strategic transaction valued at two billion US dollars. The healthcare deal was announced on 11 October…

Buyer: STERIS Corporation
Target: Xodus Medical, Inc.
Deal value: USD 2,100,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

9 October 2026CompletedHealthcare

Hepion Pharmaceuticals, Inc. to acquire Gravitas Life Sciences, LLC

Hepion Pharmaceuticals, Inc. has agreed to acquire Gravitas Life Sciences, LLC in a strategic acquisition. The transaction, valued at 4.25 million US dollars, was comple…

Buyer: Hepion Pharmaceuticals, Inc.
Target: Gravitas Life Sciences, LLC
Deal value: USD 4,250,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

Buyer history

OpenAI

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive